Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Khera, Nandita  [Clear All Filters]
Journal Article
Khera N, Majhail NS, Brazauskas R, Wang Z, He N, Aljurf MD, Akpek G, Atsuta Y, Beattie S, Bredeson CN, et al. Comparison of Characteristics and Outcomes of Trial Participants and Non-participants: Example of Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Biol Blood Marrow Transplant. 2015.
Kim W, Bangerter LR, Jo S, Langer S, Larkey L, Griffin J, Khera N. Feasibility and Acceptability of a 3-day Group-based Digital Storytelling Workshop among Caregivers of Allogeneic Hematopoietic Cell Transplant Patients: A Mixed Methods Approach. Biol Blood Marrow Transplant. 2019.
Kim WSunny, Langer S, Todd M, Larkey L, Jo S, Bangerter LR, Khera N. Feasibility of a Digital Storytelling Intervention for Hematopoietic Cell Transplant Patients. J Cancer Educ. 2021.
Bangerter LR, Looze M, Barry B, Harder K, Griffin J, Dezutter M, Khera N, Ailawadhi S, Schaepe K, Fischer K. A hybrid method of healthcare delivery research and human-centered design to develop technology-enabled support for caregivers of hematopoietic stem cell transplant recipients. Support Care Cancer. 2021.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Paulson K, Brazauskas R, Khera N, He N, Majhail N, Akpek G, Aljurf M, Buchbinder D, Burns L, Beattie S, et al. Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2019.
Yang M-J, Yepez VV, Brandon KO, Reblin M, Pidala J, Jim HSL, Meyer JS, L Gore R, Khera N, Lau P, et al. A mindfulness-based stress management program for caregivers of allogeneic hematopoietic stem cell transplant (HCT) patients: Protocol for a randomized controlled trial. PLoS One. 2022;17(4):e0266316.
Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, et al. Predictors of lost to follow-up among pediatric and adult hematopoietic cell transplant survivors: A report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2019.
Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, A Al-Homsi S, Aljurf M, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018.
Jain T, Kosiorek HE, Grys TE, Kung STing, Shah VS, Betcher JA, Slack JL, Leis JF, Khera N, Noel P, et al. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation. Leuk Lymphoma. 2018:1-8.